Previous PostLimFlow Expands Senior Management Team and Opens Silicon Valley Office
Next PostLimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients
